Insider Transactions in Q2 2021 at Xenon Pharmaceuticals Inc. (XENE)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 28
2021
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Open market or private sale
|
Direct |
6,067
-8.26%
|
$109,206
$18.81 P/Share
|
|
May 28
2021
|
Sherrington Robin EVP, Strategy & Innovation |
SELL
Payment of exercise price or tax liability
|
Direct |
4,216
-6.18%
|
$75,888
$18.91 P/Share
|
|
May 28
2021
|
Sherrington Robin EVP, Strategy & Innovation |
BUY
Exercise of conversion of derivative security
|
Direct |
25,719
+27.29%
|
$77,157
$3.81 P/Share
|
|
May 27
2021
|
Frank A Holler Director |
SELL
Open market or private sale
|
Direct |
11,064
-3.62%
|
$199,152
$18.69 P/Share
|
|
May 27
2021
|
Frank A Holler Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,418
-2.04%
|
$115,524
$18.88 P/Share
|
|
May 27
2021
|
Frank A Holler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
39,094
+10.36%
|
$117,282
$3.76 P/Share
|
|
May 24
2021
|
Simon N. Pimstone |
SELL
Payment of exercise price or tax liability
|
Direct |
5,076
-2.18%
|
$96,444
$19.17 P/Share
|
|
May 24
2021
|
Simon N. Pimstone |
BUY
Exercise of conversion of derivative security
|
Direct |
22,633
+8.86%
|
$67,899
$3.76 P/Share
|
|
May 18
2021
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+2.92%
|
$10,500
$3.85 P/Share
|
|
May 18
2021
|
Michael M Tarnow Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,229
+3.46%
|
$24,687
$3.74 P/Share
|